Some of the most advanced medical research today involves understanding the cellular and molecular pathways of disease, and at Millennium, we strongly believe that the ubiquitin-proteasome pathway (UPP) is one of the most important of these pathways in biology and medicine.
As the world leader in the field of proteasome inhibition, Millennium is committed to exploring the full potential of the UPP across multiple disease areas. Millennium is committed not only to advancing the science behind this pathway, but also to the application of this science to drug discovery and development with the aim of identifying important new medicines that will make a difference in patients' lives. By continuing its close ties to academic, government and corporate research institutions, Millennium expects to deliver on its promise of breakthrough medicines targeting the UPP and other areas of disease biology.
For more information and details, please visit the Millennium web site at www.millennium.com.
Boston Biochem, Inc. is the world's leading producer of Ubiquitin Proteasome Pathway (UPP) related reagents. Since 1997, it has been our mission to provide UPP researchers with innovative tools that facilitate and accelerate drug discovery efforts. Our extensive expertise and close relationship with the UPP research community allows us to offer the most comprehensive product range available. Key to the Boston Biochem offering is our ability to provide custom services and bulk manufacturing. All of our specialized tools are developed, produced and characterized in-house with a commitment to excellence.
Boston Biochem continually adds new products to keep current with the discoveries and requirements
of the UPP researcher. Our knowledge base, customer service and technical support are second to none. Boston Biochem has manufacturing and distribution facilities in the USA. Our products are available throughout Europe and Asia Pacific via the Axxora® platform.
Please contact us with any inquiries, suggestions or feedback. For more information please visit www.bostonbiochem.com.
